c-Met may be a biomarker for metastatic hepatocellular carcinoma
Saturday, October 2, 2010 - 21:41
in Health & Medicine
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma who have c-Met-positive tumors, according to new study results.